4/A: SOPHiA GENETICS Executive Adjusts Ownership Filings

SOPHiA GENETICS SA Chief Sales Officer Kevin Puylaert files an amended Form 4 to correct previously reported beneficial ownership of ordinary shares and details a new share option grant.

Summary

• Kevin Puylaert, Chief Sales Officer at SOPHiA GENETICS SA, has filed an amended Form 4 (Form 4/A) to correct an error in a previous filing dated April 3, 2026.
• The correction pertains to the amount of ordinary shares beneficially owned, which was initially reported as 56,468 but is now accurately stated as 148,854.
• The filing also reports a new grant of 82,335 share options with an exercise price of $5.04, vesting over several years.
• Additionally, 56,468 restricted stock units (RSUs) were granted, representing a contingent right to receive ordinary shares.
• These RSUs will vest over time, with 25% vesting on April 2, 2027, and the remainder vesting quarterly through April 2, 2030.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, primarily an administrative correction and standard equity grant disclosure, with no immediate positive or negative financial implications evident.

Positives

• Correction of beneficial ownership amount to a higher figure (148,854 shares) may indicate a more substantial stake than previously reported.
• Grant of new share options (82,335) and RSUs (56,468) suggests continued incentive alignment for key management with company performance.
• The vesting schedule for RSUs and options is spread over several years, promoting long-term retention and commitment.

Negatives

• An amendment to a previous filing indicates an initial error in reporting, which could raise minor concerns about reporting accuracy.
• The exercise price of the share options ($5.04) is a key reference point for future stock performance; the stock price would need to exceed this for the options to be profitable.

Risks

• The vesting of RSUs and share options is contingent on the Reporting Person's continued service with the Issuer, implying a risk of forfeiture if employment ceases before vesting.
• The value of the share options is subject to market fluctuations and the company's stock performance.

Future Outlook

The filing details vesting schedules for RSUs and share options extending through April 2, 2030, indicating a long-term commitment and incentive structure for the Chief Sales Officer.

Management Comments

• The filing is an amendment to correct a previous reporting error regarding the amount of ordinary shares beneficially owned.
• Details the grant of restricted stock units (RSUs) and share options, outlining their vesting schedules and exercise prices.

Industry Context

StockSavvy.ai notes that insider transactions, particularly grants of equity awards and adjustments to ownership filings, are common in the biotechnology and healthcare technology sectors as companies use them to attract and retain key talent. The specific details of vesting schedules and exercise prices provide insight into management's long-term incentives.

Stakeholder Impact

• Shareholders: The correction to a higher beneficial ownership figure for a key executive might be viewed positively, suggesting increased alignment. The equity grants are standard compensation tools.
• Employees: The equity grants signal the company's commitment to retaining key personnel through long-term incentives.
• Management: The filing directly impacts the reporting person, Kevin Puylaert, by detailing his equity awards and ownership.

Next Steps

• Monitoring of Kevin Puylaert's beneficial ownership as RSUs and options vest.
• Observation of SOPHiA GENETICS SA's stock performance relative to the share option exercise price.

Key Dates

Keywords

SOPHiA GENETICS SA, Form 4/A, Kevin Puylaert, Beneficial Ownership, Ordinary Shares, Restricted Stock Units, RSU Grant, Share Options, Equity Incentive Plan, Insider Trading, SEC Filing